The Psychosocial and Economic Burden of Genital Warts (GWburden)
Recruitment status was Not yet recruiting
Female Genital Warts
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||The Psychosocial and Economic Burden of Genital Warts for Women Attending Six Reproductive Health Clinics in Brazil|
|Study Start Date:||January 2012|
|Estimated Study Completion Date:||October 2012|
120 women attending reproductive health clinics will be interwied using HPV Impact Profile (HIP) and a socio-economic characteristics questionnaire.
Medical records of 100 patients diagnosed with genital warts will be reviewed in the six BEMFAM's participating reproductive health clinics
Cervical cancer is a public health issue in Brazil. The Cancer National Institute estimates that cervical cancer will be the second most incident among women, with 18.430 new cases in 2010. Human papillomavirus (HPV) is related to cervical cancer and is also responsible for benign lesions, such as genital warts.The Brazilian Ministry of Health estimates the prevalence of genital warts to be 5,7% among pregnant women and 21,5% among women attending sexually transmitted infections treatment clinics.The study will measure the psychosocial burden of genital warts using HPV Impact Profile questionnaire and the economic burden of genital warts among women attending its six reproductive health clinics.
There are two study objectives:
1 - to measure the psychosocial burden of genital warts in women attending six reproductive health clinics in Brazil. 2- to measure the economic burden of genital warts treatment for women attending six reproductive health clinics in Brazil.
For objective 1, the experiment compare differences on psychosocial burden of Genital Warts among subgroups and therefore does not include any formal hypothesis testing about the psychosocial burden of the disease in agreement with the extant literature on the subject (Xingshu Zhu et al., 2009).
Objective 2 aims to measure differentials in the economic burden of the disease among subgroups with different type of genital warts (newly diagnosed, recurrent and resistant), site of the lesion, age, duration of treatment, number of medical visits, type and number of medical procedures. No formal hypothesis will be tested.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01520194
|Contact: Monica G Almeida, MD, MS||55 21 email@example.com|
|Contact: Marcio T Thome, MS||55 21 firstname.lastname@example.org|
|Principal Investigator:||Monica G Almeida, MD, MS||BEMFAM Bem Estar Familiar no Brasil|